- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Patients taking Zuranolone for major depression symptoms showed quick mood improvements: Phase 3 trial
USA: A recent study published in The American Journal of Psychiatry supports the potential of zuranolone for treating a major depressive disorder in adults.
The study showed that zuranolone at 50 mg/day led to mood improvements in patients within days of treatment and was well-tolerated with no new safety findings compared with previously studied lower dosages. Zuranolone is a once-daily, oral neuroactive steroid that acts on GABA-A (γ-aminobutyric acid type A) receptors.
"Zuranolone at 50 mg/day elicited a remarkably greater improvement in depressive symptoms at day 15, with a rapid time to effect (day 3)," the researchers wrote in their study.
Anita H. Clayton from the University of Virginia School of Medicine and colleagues aimed to evaluate the safety and efficacy of a 14-day treatment course of once-daily zuranolone 50 mg, an investigational oral positive allosteric modulator of the GABAA receptor, for the treatment of major depressive disorder in a double-blind, randomized, placebo-controlled trial.
The study enrolled patients 18–64 with severe major depressive disorder. Patients were self-administered once daily zuranolone 50 mg or placebo for 14 days. A change in total score on the 17-item HAM-D (Hamilton Depression Rating Scale) on day 17 was noted. The incidence of adverse events was used to assess safety and tolerability.
534 (268 in the placebo group, 266 in the zuranolone group) constituted the complete analysis set of 543 randomized patients.
The study led to the following findings:
· Compared with patients in the placebo group, the zuranolone group demonstrated a statistically significant improvement in depressive symptoms at day 15 (least squares mean change from baseline HAM-D score, −14.1 versus −12.3).
· Numerically more significant improvements in depressive symptoms were observed for zuranolone versus placebo by day 3 (least squares mean change from baseline HAM-D score, −9.8 versus −6.8), which were sustained at all visits throughout the treatment and follow-up study periods (through day 42, with the difference remaining nominally significant through day 12).
· Two patients in each group experienced a severe adverse event; four in the placebo group and nine patients in the zuranolone group discontinued treatment due to adverse events.
"The findings showed that Zuranolone was generally well tolerated, with no new safety findings versus previously studied lower dosages," the researchers wrote. "These findings support zuranolone's potential in treating adults with major depressive disorder."
Reference:
The study, "Zuranolone for the Treatment of Adults With Major Depressive Disorder: A Randomized, Placebo‐Controlled Phase 3 Trial," was published in The American Journal of Psychiatry.
DOI: https://doi.org/10.1176/appi.ajp.20220459
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751